Search Results 1-10 of 28377 for ������������������������������������������r���:PC53���

  1. Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas - Mayo Clinic

    Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's ...

  2. Overview - Infection and Immunity: Raymund R. Razonable - Mayo Clinic Research

    The Infection and Immunity Lab of Raymund R. Razonable, M.D., at Mayo Clinic studies COVID-19 and transplant-related infections such as cytomegalovirus ...

  3. (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive - Mayo Clinic

    (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive.

  4. A Study of R-ICE and Lenalidomide for Treating Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma - Mayo Clinic

    The purpose of this study is to assess the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R ...

  5. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, predictive biomarkers and pharmacokinetics/ pharmacodynamics of ...

  6. R-3750 in Patients With Mild to Moderate Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to determine safety and tolerability of orally delivered R-3750 in mild to moderate patients with ulcerative colitis. Participation ...

  7. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

    Subjects will be randomized 1:1 to R-CHOP plus enzastaurin or R CHOP (plus placebo during induction). All subjects will receive up to 6 cycles (3 weeks per ...

  8. Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients - Mayo Clinic

    The purpose of this study is to compare the effectiveness and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to ...

  9. Everolimus R-CHOP Combination Safe for Treating Diffuse Large B-Cell Lymphoma - Mayo Clinic News Network

    Close up of IV drip for patient and Infusion pump in hospital. ROCHESTER, Minn. — The targeted therapy everolimus may be safely combined with R-CHOP for new, ...

  10. Publications - R John Presutti, D.O. - Mayo Clinic

    Klatte DCF, Starr JS, Clift KE, Hardway HD, van Hooft JE, van Leerdam ME, Potjer TP, Presutti RJ, Riegert-Johnson DL, Wallace MB, Bi Y. Utilization and ...